Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 401–500 of 1,019

The Cell Biology of LRRK2 in Parkinson's Disease
Usmani, A., Shavarebi, F., & Hiniker, A. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00660-20 · Cited by 107
The cannabinoid system and microglia in health and disease
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem‐Taylor, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108555 · Cited by 103
Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine
dos Santos, J. R., Cunha, J. A., Dierschnabel, A. L., Campêlo, C. L. D. C., Leão, A. H. F. F., Silva, A. F., Engelberth, R. C. G. J., Izídio, G. S., Cavalcante, J. S., Abílio, V. C., et al. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.06.031 · Cited by 97
“[1] De Lau LML, Breteler MMB.”
Background
Quality of life scale in parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation
Souza, R. G., Borges, V., Gomes, S. M. C. D. A. S. M. M., & Ferraz, H. B. (2007) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2007000500010 · Cited by 94
Corynoxine, a Natural Autophagy Enhancer, Promotes the Clearance of Alpha-Synuclein via Akt/mTOR Pathway
Chen, L., Song, J., Lu, J., Yuan, Z., Liu, L., Durairajan, S. S. K., & Li, M. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9528-2 · Cited by 97
Event-related potentials and cognition in Parkinson’s disease: An integrative review
Seer, C., Lange, F., Georgiev, D., Jahanshahi, M., & Kopp, B. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.08.003 · Cited by 100
“1.1 Cognition in Parkinson’s disease PD is one of the most common neurodegenerative disorders, with an incidence of 8–18 per 100,000 person-years (de Lau and Breteler, 2006).”
BackgroundInfluential
Effects of an Innovative Telerehabilitation Intervention for People With Parkinson's Disease on Quality of Life, Motor, and Non-motor Abilities
Isernia, S., Tella, S. D., Pagliari, C., Jonsdottir, J., Castiglioni, C., Gindri, P., Salza, M., Gramigna, C., Palumbo, G., Molteni, F., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00846 · Cited by 101
The VPS35 gene and Parkinson's disease
Deng, H., Gao, K., & Jankovic, J. J. (2013) · Movement Disorders · doi:10.1002/mds.25430 · Cited by 96
A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism
Trinh, J., Amouri, R., Duda, J. E., Morley, J. F., Read, M., Donald, A., Vilariño‐Güell, C., Thompson, C., Szu‐Tu, C., Gustavsson, E. K., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.015 · Cited by 95
“…characterized by resting tremor, bradykinesia, rigidity, and postural instability (Fahn, 2003). iPD affects more than 1% of the population at the age of 65 years and 4%e5% at the age of 85 years but is steadily increasing in prevalence with increased life expectancy (de Lau and Breteler, 2006).”
Background
FABP3 Protein Promotes α-Synuclein Oligomerization Associated with 1-Methyl-1,2,3,6-tetrahydropiridine-induced Neurotoxicity
Shioda, N., Yabuki, Y., Kobayashi, Y., Onozato, M., Owada, Y., & Fukunaga, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.527341 · Cited by 99
Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Boeve, B. F., Graff‐Radford, J., Rocca, W. A., & Mielke, M. M. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0603 · Cited by 97
The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson’s Disease: A Systematic Review and Meta-Analysis
Zhou, Z., Zhou, R., Zhang, Z., & Li, K. (2019) · Medical Science Monitor · doi:10.12659/msm.912840 · Cited by 95
Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinson’s Disease: A Review
Malar, D. S., Prasanth, M. I., Brimson, J. M., Sharika, R., Sivamaruthi, B. S., Chaiyasut, C., & Tencomnao, T. (2020) · Molecules · doi:10.3390/molecules25173926 · Cited by 97
Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells
Plotegher, N., Gratton, E., & Bubacco, L. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.013 · Cited by 95
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Hovelsø, N., Sotty, F., Montezinho, L. P., Pinheiro, P. S., Herrik, K. F., & Mørk, A. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362805 · Cited by 100
Hormone Replacement Therapy and Risk for Neurodegenerative Diseases
Dye, R. V., Miller, K. J., Singer, E. J., & Levine, A. J. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/258454 · Cited by 99
Mitophagy and Parkinson's disease: Be eaten to stay healthy
de Vries, R. L. A., & Przedborski, S. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.07.008 · Cited by 96
Two-Year Exercise Program Improves Physical Function in Parkinson’s Disease
Prodoehl, J., Rafferty, M. R., David, F. J., Poon, C., Vaillancourt, D. E., Comella, C. L., Leurgans, S. E., Kohrt, W. M., Corcos, D. M., & Robichaud, J. A. (2014) · Neurorehabilitation and neural repair · doi:10.1177/1545968314539732 · Cited by 94
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting approximately 1% of people over age 60 and 4% over age 80.(1) The clinical progression of PD is multidimensional and leads to a wide spectrum of impairments across gait, balance, strength, and cognition, which, in turn, contribute to dimini…”
Background
Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging
Nigro, S. L., Riccelli, R., Passamonti, L., Arabia, G., Morelli, M., Nisticò, R., Novellino, F., Salsone, M., Barbagallo, G., & Quattrone, A. (2016) · Human Brain Mapping · doi:10.1002/hbm.23324 · Cited by 96
Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
Santiago, J. A., Bottero, V., & Potashkin, J. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00394 · Cited by 98
Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study
Yin, W., Löf, M., Pedersen, N. L., Sandin, S., & Fang, F. (2020) · Movement Disorders · doi:10.1002/mds.28314 · Cited by 97
Synaptic vesicle trafficking and Parkinson's disease
Esposito, G., Clara, F. A., & Verstreken, P. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20916 · Cited by 101
“PD is the second most frequent neurodegenerative disorder (de Lau and Breteler, 2006).”
Background
Preventing α-synuclein aggregation: The role of the small heat-shock molecular chaperone proteins
Cox, D., Carver, J. A., & Ecroyd, H. W. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.024 · Cited by 98
Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases
Fernández‐Moriano, C., González‐Burgos, E., & Gómez-Serranillos, M. P. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/408927 · Cited by 100
Visual signs and symptoms of Parkinson's disease
Armstrong, R. A. (2007) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2007.00211.x · Cited by 94
Induction of Human Mesenchymal Stem Cells into Dopamine-Producing Cells with Different Differentiation Protocols
Barzilay, R., Kan, I., Ben‐Zur, T., Bulvik, S., Melamed, E., & Offen, D. (2008) · Stem Cells and Development · doi:10.1089/scd.2007.0172 · Cited by 94
“5% of the elderly population [1].”
Interactions of sex and aging on spatiotemporal metrics in non-pathological gait: a descriptive meta-analysis
Frimenko, R. E., Goodyear, C. D., & Bruening, D. A. (2015) · Physiotherapy · doi:10.1016/j.physio.2015.01.003 · Cited by 93
“[6] de Lau LML, Breteler MMB.”
Background
Evidence-based treatment of voice and speech disorders in Parkinson disease
Mahler, L. A., Ramig, L. O., & Fox, C. (2015) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000151 · Cited by 93
Cognitive phenotypes in parkinson's disease differ in terms of brain‐network organization and connectivity
Lopes, R., Delmaire, C., Defebvre, L., Moonen, A. J. H., Duits, A., Hofman, P. A. M., Leentjens, A. F. G., & Dujardin, K. (2016) · Human Brain Mapping · doi:10.1002/hbm.23474 · Cited by 91
“Parkinson’s disease is a neurodegenerative disease affecting more than 1% of the population over the age of 60 [de Lau and Breteler, 2006].”
Background
Classification of advanced stages of Parkinson’s disease: translation into stratified treatments
Krüger, R., Klucken, J., Weiß, D., Tönges, L., Kolber, P. L., Unterecker, S., Lorrain, M., Baas, H. K. J., Müller, T. H., & Riederer, P. F. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1707-x · Cited by 94
Occupational exposure to chronic ionizing radiation increases risk of Parkinson's disease incidence in Russian Mayak workers
Azizova, T. V., Bannikova, M. V., Grigoryeva, E. S., Rybkina, V. L., & Hamada, N. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyz230 · Cited by 93
Minority enrollment in Parkinson's disease clinical trials
Schneider, M. G., Swearingen, C. J., Shulman, L. M., Ye, J., Baumgarten, M., & Tilley, B. C. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.06.005 · Cited by 93
“Parkinson’s disease (PD) is a chronic, degenerative and incurable neurological disorderwhich causes aprogressive loss of independence resulting in significant disability and considerable financial burden to medical care systems [1–4].”
Background
Changes in Executive Function After Acute Bouts of Passive Cycling in Parkinson’s Disease
Ridgel, A. L., Kim, C., Fickes, E. J., Muller, M. D., & Alberts, J. L. (2011) · Journal of Aging and Physical Activity · doi:10.1123/japa.19.2.87 · Cited by 93
“Parkinson’s disease is a progressive neurological disorder that affects 1 in 100 individuals over the age of 60 (de Lau & Breteler, 2006).”
Background
White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract–Specific Analysis
Kamagata, K., Motoi, Y., Abe, O., Shimoji, K., Hori, M., Nakanishi, A., Sano, T., Kuwatsuru, R., Aoki, S., & Hattori, N. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2860 · Cited by 92
Aberrant regional homogeneity in Parkinson’s disease: A voxel-wise meta-analysis of resting-state functional magnetic resonance imaging studies
Pan, P., Zhan, H., Xia, M., Zhang, Y., Guan, D., & Xu, Y. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.018 · Cited by 93
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Type‐1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease
Main, B. S., Zhang, M., Brody, K. M., Ayton, S., Frugier, T., Steer, D., Finkelstein, D., Crack, P. J., & Taylor, J. M. (2016) · Glia · doi:10.1002/glia.23028 · Cited by 92
“1590 VC 2016 Wiley Periodicals, Inc. of the population aged 60 years of age (de Lau and Breteler, 2006).”
Background
Delirium and High Fever Are Associated with Subacute Motor Deterioration in Parkinson Disease: A Nested Case-Control Study
Umemura, A., Oeda, T., Tomita, S., Hayashi, R., Kohsaka, M., Park, K., Sugiyama, H., & Sawada, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094944 · Cited by 92
“Dopaminergic neuronal degeneration progresses insidiously and constantly; accordingly, motor disturbance deteriorates gradually in most patients [1–3].”
Background
Epigenetic Landscape of Parkinson's Disease: Emerging Role in Disease Mechanisms and Therapeutic Modalities
Kaidery, N. A., Tarannum, S., & Thomas, B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0211-8 · Cited by 93
Meta‐Analysis of Copper and Iron in Parkinson's Disease Brain and Biofluids
Genoud, S., Senior, A. M., Hare, D. J., & Double, K. L. (2019) · Movement Disorders · doi:10.1002/mds.27947 · Cited by 95
Stem Cell-Based Therapies for Parkinson Disease
Liu, Z., & Cheung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218060 · Cited by 98
“Most neurodegenerative processes related to PD are driven by the accumulation of pathological α-synuclein (α-syn) [5], which is a presynaptic neuronal protein that aggregates to form Lewy bodies (LBs) and Lewy neurites (LNs) in the nervous system [6,7].”
Background
Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease
Sela, M., Poley, M., Mora‐Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304654 · Cited by 93
Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve
Machhada, A., Ang, R., Ackland, G. L., Ninkina, N., Buchman, V. L., Lythgoe, M. F., Trapp, S., Tinker, A., Marina, N., & Gourine, A. V. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.06.005 · Cited by 93
High-Convexity Tightness Predicts the Shunt Response in Idiopathic Normal Pressure Hydrocephalus
Narita, W., Nishio, Y., Baba, T., Iizuka, O., Ishihara, T., Matsuda, M., Iwasaki, M., Tominaga, T., & Mori, E. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4838 · Cited by 91
Dopamine beta‐hydroxylase and its genetic variants in human health and disease
Gonzalez‐Lopez, E., & Vrana, K. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14893 · Cited by 91
“Despite documented cases of PD from ancient times, in early western medical literature, and from rigorous research in humans, animal and cell models, the etiology remains idiopathic (Braak et al. 2006; de Lau and Breteler 2006).”
Background
Use of radiomic features and support vector machine to distinguish Parkinson’s disease cases from normal controls
Wu, Y., Jiang, J., Chen, L., Lu, J., Ge, J., Liu, F., Yu, J., Lin, W., Zuo, C., & Wang, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.26 · Cited by 91
“Moreover, the prevalence of PD is increasing year by year as the population ages, and is expected to cause huge economic and social burden to society (6).”
Background
Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform
Pinto, M., Silva, V., Barreiro, S., Silva, R. V. D. S., Remião, F., Borges, F., & Fernandes, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101658 · Cited by 97
Surface EMG and acceleration signals in Parkinson’s disease: feature extraction and cluster analysis
Rissanen, S. M., Kankaanpaa, M. J., Meigal, A. Y., Tarvainen, M. P., Nuutinen, J., Tarkka, I. M., Airaksinen, O., & Karjalainen, P. A. (2008) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-008-0369-0 · Cited by 92
Coding mutations in NUS1 contribute to Parkinson’s disease
Guo, J., Zhang, L., Li, K., Mei, J., Xue, J., Chen, J., Tang, X., Shen, L. H., Jiang, H. F., Chen, C., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809969115 · Cited by 92
“The prevalence of PD is ∼1–2% in people over the age of 60 y and up to 4% in people older than 80 y (2).”
Background
Eryptosis as a marker of Parkinson's disease
Pretorius, E., Swanepoel, A. C., Buys, A. V., Vermeulen, N., Duim, W., & Kell, D. B. (2014) · Aging · doi:10.18632/aging.100695 · Cited by 95
Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca 2+
Toulorge, D., Guerreiro, S., Hild, A., Maskos, U., Hirsch, É. C., & Michel, P. P. (2011) · The FASEB Journal · doi:10.1096/fj.11-182824 · Cited by 89
Prevalence of Alzheimer's Disease and Parkinson's Disease in China: An Updated Systematical Analysis
Cui, L., Hou, N.-N., Wu, H., Zuo, X., Lian, Y.-Z., Zhang, C., Wang, Z., Zhang, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.603854 · Cited by 88
Concise Review: Adult Mesenchymal Stem Cells, Adult Neural Crest Stem Cells, and Therapy of Neurological Pathologies: A State of Play
Neirinckx, V., Coste, C., Rogister, B., & Wislet‐Gendebien, S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0147 · Cited by 88
Reduced risk of Parkinson’s disease associated with lower body mass index and heavy leisure-time physical activity
Sääksjärvi, K., Knekt, P., Männistö, S., Lyytinen, J., Jääskeläinen, T., Kanerva, N., & Heliövaara, M. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9887-2 · Cited by 88
Gallic Acid Protects 6-OHDA Induced Neurotoxicity by Attenuating Oxidative Stress in Human Dopaminergic Cell Line
Chandrasekhar, Y., Kumar, G. P., Ramya, E. M., & Anilakumar, K. R. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2530-y · Cited by 90
Role of Dietary Supplements in the Management of Parkinson’s Disease
Ciulla, M., Marinelli, L., Cacciatore, I., & Stefano, A. D. (2019) · Biomolecules · doi:10.3390/biom9070271 · Cited by 96
“PD affects approximately 1% of individuals older than 60 years, with an increment in the incidence of 5–10 times from the sixth to the ninth decade of life [12].”
Background
From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease
Millan, M. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.002 · Cited by 92
Comorbidity and Chronic Conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2
Vasilopoulos, T., Kotwal, A., Huisingh-Scheetz, M. J., Waite, L. J., McClintock, M. K., & Dale, W. (2014) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbu025 · Cited by 88
Current trends in etiology, prognosis and therapeutic aspects of Parkinson's disease: a review.
Jagadeesan, A. J., Murugesan, R., Devi, S. V., Meera, M. V. S., Madhumala, G., Padmaja, M. V., Ramesh, A., Banerjee, A., Sushmitha, S., Khokhlov, A. N., et al. (2017) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v88i3.6063 · Cited by 89
Akkermansia muciniphila induces mitochondrial calcium overload and α -synuclein aggregation in an enteroendocrine cell line
Neto, D. P. A., Bosque, B. P., de Godoy, J. V. P., Rodrigues, P. V., Meneses, D. D., Tostes, K., Tonoli, C. C. C., Carvalho, H. F., González-Billault, C. E., & Fonseca, M. D. C. (2022) · iScience · doi:10.1016/j.isci.2022.103908 · Cited by 90
Diffusion along perivascular spaces provides evidence interlinking compromised glymphatic function with aging in Parkinson's disease
Cai, X., Chen, Z., He, C., Zhang, P., Nie, K., Qiu, Y., Wang, L., Wang, L., Jing, P., & Zhang, Y. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13984 · Cited by 86
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
Ebrahimi‐Fakhari, D., Saidi, L.-J., & Wahlster, L. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-79 · Cited by 89
Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993
Tüchsen, F., & Jensen, A. A. (2000) · Scandinavian Journal of Work Environment & Health · doi:10.5271/sjweh.554 · Cited by 87
Genetic mutations and functions of PINK1
Kawajiri, S., Saiki, S., Sato, S., & Hattori, N. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.001 · Cited by 87
Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis
Fang, X. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1096271 · Cited by 84
Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants
Klein, P., Müller-Rischart, A. K., Motori, E., Schönbauer, C., Schnorrer, F., Winklhofer, K. F., & Klein, R. (2014) · The EMBO Journal · doi:10.1002/embj.201284290 · Cited by 90
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease
Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5157 · Cited by 84
Parkinson Disease
Zesiewicz, T. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000764 · Cited by 86
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance – Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study
Meng, Y., Pople, C. B., Huang, Y., Jones, R. M., Ottoy, J., Goubran, M., de Oliveira, L. M., Davidson, B., Lawrence, L., Lau, A. Z., et al. (2022) · Movement Disorders · doi:10.1002/mds.29190 · Cited by 86
Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration
Wales, P., Pinho, R., Lázaro, D. F., & Outeiro, T. F. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130216 · Cited by 89
An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders
Yang, Y., Jiang, S., Yan, J., Li, Y., Xin, Z., Yan, L., & Qu, Y. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.09.002 · Cited by 86
“substantia nigra (SN), a region of the midbrain [76].”
Background
Validation of the brazilian version of the berg balance scale for patients with parkinson's disease
Scalzo, P. L., Nova, I. C., Perracini, M. R., Sacramento, D., Cardoso, F., Ferraz, H. B., & Teixeira, A. L. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000500010 · Cited by 86
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism
Halliday, G. M., Herrero, M. T., Murphy, K., McCann, H., Ros‐Bernal, F., Barcia, C., Mori, H., Blesa, F. J., & Obeso, J. A. (2009) · Movement Disorders · doi:10.1002/mds.22481 · Cited by 86
Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease
O’Keeffe, G. W., & Sullivan, A. M. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.025 · Cited by 85
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder that affects 1-2% of the population over the age of 60 [1-3].”
Background
Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
Ibáñez, L., Dube, U., Saef, B. A., Budde, J., Black, K., Medvedeva, A., Del‐Aguila, J. L., Davis, A. A., Perlmutter, J. S., Harari, O., et al. (2017) · BMC Neurology · doi:10.1186/s12883-017-0978-z · Cited by 85
Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing
Ullah, H., & Khan, H. Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00422 · Cited by 85
“Approximately 1–2% of the population suffers from PD over the age of 65 years and this figure increases to 3–5% in people of 85 years and older (De Lau and Breteler, 2006; Alves et al., 2008).”
Background
Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis
Eversfield, C. L., & Orton, L. D. (2018) · Psychological Medicine · doi:10.1017/s0033291718003161 · Cited by 85
“Estimates suggest PD prevalence is 1% in people over 60 (De Lau and Breteler, 2006), while DLB has a prevalence of 0.4% in people over 65 (Vann Jones and O ’ Brien, 2014).”
Influential
Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study
Winter, Y., von Campenhausen, S., Arend, M., Longo, K., Boetzel, K., Eggert, K. M., Oertel, W. H., Dodel, R. C., & Barone, P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.01.003 · Cited by 85
The role of regulatory T cells in nervous system pathologies
Duffy, S. S., Keating, B. A., Perera, C. J., & Moalem‐Taylor, G. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24073 · Cited by 88
Tea Polyphenols in Parkinson’s Disease
Caruana, M., & Vassallo, N. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18365-7_6 · Cited by 88
Rapid eye movement sleep behavior disorder as a biomarker for neurodegeneration: The past 10years
Postuma, R. B., Gagnon, J., & Montplaisir, J. Y. (2012) · Sleep Medicine · doi:10.1016/j.sleep.2012.09.001 · Cited by 84
“Based on known incidence rates [11], identifying 20 patients with incident PD would require 10,000 patients age >60 followed for 5 years.”
Background
Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: Comparison with conventional diffusion tensor imaging
Kamagata, K., Tomiyama, H., Motoi, Y., Kano, M., Abe, O., Ito, K., Shimoji, K., Suzuki, M., Hori, M., Nakanishi, A., et al. (2013) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2013.06.009 · Cited by 85
“Parkinson disease (PD)—the most common human neurodegenerative disorder after Alzheimer disease [1]—is classically characterized by resting tremor, slowness of initial movement, rigidity, and general postural instability.”
Background
MicroRNA-7 inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax and Sirt2.
Li, S., Lv, X., Zhai, K., Xu, R., Zhang, Y., Zhao, S., Qin, X., Yin, L., & Lou, J. (2016) · PubMed · Cited by 84
Biological functions of selenium and its potential influence on Parkinson's disease
Ellwanger, J. H., Franke, S. I. R., Bordin, D. L., Prá, D., & Henriques, J. A. P. (2016) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201620150595 · Cited by 88
Genetics of Parkinson’s disease and related disorders
Zhang, P.-L., Chen, Y., Zhang, C.-H., Wang, Y., & Fernández-Fúnez, P. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105047 · Cited by 93
Preclinical progression of neurodegenerative diseases.
Katsuno, M., Sahashi, K., Iguchi, Y., & Hashizume, A. (2018) · Europe PMC (PubMed Central) · doi:10.18999/nagjms.80.3.289 · Cited by 88
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease
Elfil, M., Bahbah, E. I., Attia, M. M., Eldokmak, M., & Koo, B. B. (2020) · Movement Disorders · doi:10.1002/mds.28412 · Cited by 88
The Signaling and Pharmacology of the Dopamine D1 Receptor
Jones-Tabah, J., Mohammad, H., Paulus, E., Clarke, P. B. S., & Hébert, T. E. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.806618 · Cited by 97
Comparing the Incidence of Falls/Fractures in Parkinson’s Disease Patients in the US Population
Kalilani, L., Asgharnejad, M., Palokangas, T., & Durgin, T. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161689 · Cited by 84
Association between Open-Angle Glaucoma and the Risks of Alzheimer’s and Parkinson’s Diseases in South Korea: A 10-year Nationwide Cohort Study
Moon, J. Y., Kim, H. J., Park, Y. H., Park, T. K., Park, E., Kim, C. Y., & Lee, S. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-29557-6 · Cited by 84
Research in Parkinson′s disease in India: A review
Pal, P., Surathi, P., Jhunjhunwala, K. R., & Yadav, R. (2015) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.167713 · Cited by 83
Prediction of Cognitive Decline in Parkinson’s Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems
Hosseinzadeh, M., Gorji, A., Jouzdani, A. F., Rezaeijo, S. M., Rahmim, A., & Salmanpour, M. R. (2023) · Diagnostics · doi:10.3390/diagnostics13101691 · Cited by 85
Progress in neuroprotection in Parkinson’s disease
Schapira, A. H. V. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02055.x · Cited by 82
Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter
Strecker, K., Wegner, F., Hesse, S., Becker, G., Patt, M., Meyer, P., Lobsien, D., Schwarz, J., & Sabri, O. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5666-5 · Cited by 83
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder [7].”
Background
A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality
Sääksjärvi, K., Knekt, P., Lundqvist, A., Männistö, S., Heliövaara, M., Rissanen, H. A., & Järvinen, R. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000955 · Cited by 87
Manganese-induced neurodegenerative diseases and possible therapeutic approaches
Martins, A. C., Gubert, P., Boas, G. R. V., Paes, M. M., Santamaría, A., Lee, E.-S., Tinkov, A. A., Bowman, A. B., & Aschner, M. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1807330 · Cited by 83
Molecular Chaperones in Parkinson's Disease – Present and Future
Ebrahimi‐Fakhari, D., Wahlster, L., & McLean, P. J. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11044 · Cited by 83
NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease
Shan, S., Hong-Min, T., Yi, F., Jun-Peng, G., Yue, F. L., Yan-hong, T., Yun-ke, Y., Li, W., Wang, X., Ma, J., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.004 · Cited by 82
Antioxidant action of 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cytotoxicity
Han, X., Zhu, S., Wang, B., Chen, L., Li, R., Yao, W., & Qu, Z. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.10.018 · Cited by 82
Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection
Mounsey, R. B., & Teismann, P. (2010) · Parkinson s Disease · doi:10.4061/2011/617472 · Cited by 86

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks